Perseus Therapeutics is pioneering innovative therapies aimed at preventing hair loss, particularly in patients undergoing chemotherapy, as well as for cosmetic purposes. The company has identified thymic stromal lymphopoietin (TSLP) as a novel therapeutic target for chemotherapy-induced hair loss. By utilizing monoclonal antibodies to block TSLP, Perseus Therapeutics aims to prevent hair cycle arrest caused by chemotherapy's cytotoxic effects. This treatment can be administered through various methods, including topical, subcutaneous, or intravenous routes, and is designed to delay the onset of hair loss during chemotherapy. The efficacy of this approach has been demonstrated in vivo using wound-induction models, where the absence of the TSLP receptor in mice resulted in a failure to initiate hair cycling.

In addition to its primary focus on chemotherapy-related hair loss, the technology developed by Perseus Therapeutics has broader applications. It may also benefit patients experiencing alopecia unrelated to chemotherapy, as well as those suffering from hair loss due to various medical conditions and treatments. The blockade of TSLP not only addresses hair loss but may also serve as a potential adjuvant therapy in cancer treatment, given TSLP's role in promoting cancer growth and metastasis. Overall, Perseus Therapeutics is committed to delivering effective, science-backed solutions that enhance the quality of life for individuals facing hair loss challenges.

United States

Perseus Therapeutics, Inc. is at the forefront of innovation, dedicated to advancing the field of hair restoration.

With a deep commitment to improving the lives of individuals who have experienced hair loss due to chemotherapy or for cosmetic reasons, our mission is to offer effective, science-backed solutions that empower confidence and well-being.

Perseus Therapeutics

Company Details